Products
Preparation registered in Ukraine
K. Zuiev
Investigation the irbesartan renoprotective efficiency in patients with diabetic nephropathy
In type 2 diabetic patients with nephropathy at microalbuminuric stage was investigated renoprotective efficiencythe angiotensin-receptor antagonistirbesartan (300 mg QID) in comparison with calcium chenell-blocker amlodipine (10 mg QID) in open label study. Renal function was evaluated by determination renal functional reserve (RFR) with modified protein tolerance test with instantized milk protein. After 3 months of therapy in patients group received irbesartan (n=30) RFR significantly elevated on 490% (Ð<0,01),whereas in amlodipine group only non significant 3,6% elevation was observed (Ð>0,05). At the end of study was observed significantly decrease urine albumin excretion rate at 43% (Ð<0,05)in irbesartan group. Opposite, in amlodipine group revealed non significant elevation urine albumin excretion rate. Treatment with irbesartan accompanied significant positive alteration many metabolic parameters (glicated haemoglobin (HbA1c), triglycerides and high density lipoproteins). In addition, at the end of the study in irbesartan group, despite similar to amlodipine group blood pressure (BP) level decrease (office BP and defined in diurnal BP monitoring), positive influence on diurnal BP rhythm was determined. Thus, nephroprotective action of irbesartan depend not only from angiotensin receptors blocade, but also from many positive metabolic effects and influence on diurnal BP rhythm.
Keywords: diabetic nephropathy, functional kidney reserve, irbesartan, albuminuria, day's monitoring of arteriotony.